Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab +/- Ipilimumab with TTFields in Recurrent Glioblastoma
NCT03430791Phase 2Terminated
- Sponsor
- Baptist Health South Florida
- Start
- Dec 2018
- Primary completion
- May 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab, ipilimumab in glioblastoma (GBM), sponsored by Baptist Health South Florida. Started Dec 2018; status: terminated.
02
Drugs
nivolumabipilimumab
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT03430791.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03430791.